2242 related articles for article (PubMed ID: 24374462)
1. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
2. Herbal medicines for fatty liver diseases.
Liu ZL; Xie LZ; Zhu J; Li GQ; Grant SJ; Liu JP
Cochrane Database Syst Rev; 2013 Aug; (8):CD009059. PubMed ID: 23975682
[TBL] [Abstract][Full Text] [Related]
3. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
[TBL] [Abstract][Full Text] [Related]
5. Statins for the treatment of dementia.
McGuinness B; O'Hare J; Craig D; Bullock R; Malouf R; Passmore P
Cochrane Database Syst Rev; 2010 Aug; (8):CD007514. PubMed ID: 20687089
[TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Lewicki M; Ng I; Schneider AG
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010480. PubMed ID: 25758322
[TBL] [Abstract][Full Text] [Related]
7. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
8. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
9. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
[TBL] [Abstract][Full Text] [Related]
10. Statins for multiple sclerosis.
Wang J; Xiao Y; Luo M; Zhang X; Luo H
Cochrane Database Syst Rev; 2010 Dec; (12):CD008386. PubMed ID: 21154395
[TBL] [Abstract][Full Text] [Related]
11. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Azzalini L; Orando S; Orlando R; Angelico F
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004996. PubMed ID: 17253535
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
13. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
14. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Smith DG; McBurney CR
Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.
Fatima K; Moeed A; Waqar E; Atif AR; Kamran A; Rizvi H; Suri NF; Haider H; Shuja SH; Khalid M; Minhas AMK
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101816. PubMed ID: 34607067
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering agents for nephrotic syndrome.
Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
[TBL] [Abstract][Full Text] [Related]
17. Statins for acute ischemic stroke.
Squizzato A; Romualdi E; Dentali F; Ageno W
Cochrane Database Syst Rev; 2011 Aug; (8):CD007551. PubMed ID: 21833959
[TBL] [Abstract][Full Text] [Related]
18. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Athyros VG; Mikhailidis DP; Didangelos TP; Giouleme OI; Liberopoulos EN; Karagiannis A; Kakafika AI; Tziomalos K; Burroughs AK; Elisaf MS
Curr Med Res Opin; 2006 May; 22(5):873-83. PubMed ID: 16709309
[TBL] [Abstract][Full Text] [Related]
19. Statins for women with polycystic ovary syndrome not actively trying to conceive.
Raval AD; Hunter T; Stuckey B; Hart RJ
Cochrane Database Syst Rev; 2011 Oct; (10):CD008565. PubMed ID: 21975784
[TBL] [Abstract][Full Text] [Related]
20. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
